Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 2/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | ICMT | O60725 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15862439 | 0.85 | CETP (0.35) | CETPGAA | |
| SCHEMBL4882033 | 0.84 | MLYCD (0.42) | GAAALDH1A1KMT2A | |
| SCHEMBL1424999 | 0.80 | MAPT (0.34) | CETPGAA | |
| SCHEMBL2523541 | 0.80 | ALDH1A1 (0.41) | GAAALDH1A1MEN1KMT2A | |
| SCHEMBL1023793 | 0.80 | APP (0.37) | CETPGAA | |
| SCHEMBL15919355 | 0.80 | MAPT (0.34) | CETPGAA | |
| SCHEMBL31747633 | 0.80 | ICMT (0.40) | CETPEGLN2GAAICMTABCB1 | |
| SCHEMBL2599179 | 0.80 | MAPT (0.44) | CETPICMTALDH1A1 | |
| SCHEMBL19693281 | 0.79 | KDM4E (0.41) | CETPEGLN2GAAHDAC6ALDH1A1 | |
| SCHEMBL29519765 | 0.79 | KDM4E (0.41) | CETPEGLN2GAAHDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025261907-A1 | NONLINEAR OPTICAL DYES WITH IMPROVED STABILITY | SILORIX GMBH (DE) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667535-A1 | NONLINEAR OPTICAL DYES WITH IMPROVED STABILITY | SilOriX GmbH (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-9926314-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-03-27 | — | — | US | disclosed |
| US-9556169-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2016-11-17 | — | — | US | disclosed |
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| WO-2014078802-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | CETP 820/4885EGLN2 2991/4885GAA 747/4885 |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | CETP 820/4885EGLN2 2991/4885GAA 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.